'WHO & an independent group of experts are scheduled to meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant Emergency Use Listing to Covaxin,' the global health body tweeted.
Union Minister Nitin Gadkari on Tuesday said that more pharma companies should be allowed to manufacture the COVID-19 vaccine in the country during the pandemic to scale up production.
The World Health Organisation's technical advisory group will meet on October 26 to consider the Emergency Use Listing (EUL) of Covaxin, a vaccine developed by Hyderabad-based Bharat Biotech protecting against COVID-19, the global health agency's chief scientist said.
'Almost 70 per cent production time of a vaccine is dedicated to quality control, which is done through several hundred tests.'
The Supreme Court has asked the Centre to place on record all relevant documents and file notings reflecting its thinking culminating in the COVID-19 vaccination policy, and the purchase history till date of all jabs including Covaxin, Covishield and Sputnik V.
'Between its natural immunity with Delta, in so many populations, and then getting on top of the vaccination (situation), I do not think India is going to have another bad wave.'
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances